INKT Profile
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative cell therapies designed to treat cancer and other immune-mediated diseases. The company specializes in allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, which harness the power of a specific type of immune cell to target and destroy malignant cells. This approach represents a significant advancement in cellular immunotherapy, offering potential benefits over traditional therapies by providing ready-to-use, scalable treatment options.
The company's lead product candidate, AGENT-797, is an off-the-shelf iNKT cell therapy currently in Phase 1 clinical trials. AGENT-797 is being developed to address various myeloma diseases, including multiple myeloma, and aims to deliver targeted, durable responses by leveraging the unique properties of iNKT cells. This therapeutic approach is designed to enhance the body’s natural immune response against cancer cells, potentially leading to more effective and long-lasting treatment outcomes.
Formerly known as AgenTus Therapeutics, Inc., the company rebranded to MiNK Therapeutics, Inc. to better reflect its focus on iNKT cell therapies. Established in 2017 and headquartered in New York, New York, MiNK Therapeutics operates within a dynamic biotechnology ecosystem, benefiting from its strategic location and access to cutting-edge research and development resources. The company is a subsidiary of Agenus Inc., which provides additional support and resources to advance its mission.
MiNK Therapeutics is committed to expanding its pipeline of iNKT cell therapies and advancing the field of immunotherapy. The company’s research efforts are directed towards developing new treatment options for a range of cancers and immune-mediated conditions. By leveraging its expertise in cell therapy and collaborating with industry partners, MiNK Therapeutics aims to drive innovation and deliver transformative therapies that improve patient outcomes and address unmet medical needs in oncology and immunology.
|
